Epigenomics: Andrew Lukowiak

Epigenomics said that Andrew Lukowiak has resigned from his position of president and CSO, and as a member of the executive board, effective May 31. Lukowiak has held these positions since December 2021. The company said that his resignation is in accord with a company restructuring initiated on Feb. 15, 2023, in the wake of the company failing to raise additional capital for a pivotal study to support US Food and Drug Administration approval of its colorectal cancer screening assay.